Dmitriy Zamarin is an Oncology physician affiliated with Tisch Hospital. OpenAlex indexes 391 publications with 15,779 citations (h-index 59).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
325 W 15th St
New York, NY 100115903
Telephone
212-604-6010Provider last certified this registry record 20 Sept 2023.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Verastem, Inc.Program year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
- Gilead Sciences, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
52.1%Serotonin-3 Receptor Antagonist52.1%Ondansetron Odt100%Part D<11 patientsNervous system
25%Phenothiazine25%Prochlorperazine Maleate100%Part D<11 patientsSensory organs
22.9%Corticosteroid22.9%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Reprogramming Virus-Primed Immunity for Targeted Immunotherapy of Ovarian Cancer
Icahn School of Medicine at Mount Sinai
FY2026$696,221R01CA317668 - POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION
Icahn School of Medicine at Mount Sinai
FY2026$630,723R01CA269382 - POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION
Icahn School of Medicine at Mount Sinai
FY2025$611,086R01CA269382
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Saud Sadiq, MD
Tisch Hospital
James Ferrara, MD
Tisch Hospital
Paula Klein, MD
Tisch Hospital
Suchitra Sundaram, MD
Tisch Hospital
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”